Levofloxacin (LFX) is a highly effective anti-tuberculosis drug with a pronounced bactericidal activity against Mycobacterium tuberculosis (Mtb). In this work, an “organic solvent-free” approach has been used for the development of polylactic-co-glycolic acid (PLGA) microparticles and scaffolds containing LFX at a therapeutically significant concentration, providing for its sustained release. To achieve the target, both nonpolar supercritical carbon dioxide and polar supercritical trifluoromethane have been used. By changing the composition, surface morphology, size, and internal structure of the polymer carriers, one can control the kinetics of the LFX release into phosphate buffered saline solutions and physiological media, providing for its acceptable burst and desirable concentration in the prolonged phase. The biocompatibility and bactericidal efficacy of PLGA/LFX carriers assessed both in vitro (against Mtb phagocytosed by macrophages) and in vivo (against inbred BALB/c mice aerogenically infected with Mtb) demonstrated their anti-tuberculosis activity comparable with that of the standard daily intragastric levofloxacin administration. These results make it possible to consider the developed compositions as a promising candidate for anti-tuberculosis control release formulations providing for the further evaluation of their activity against Mtb and their metabolism in vivo over long periods of tuberculosis infection.
The growing production and use of multi-walled carbon nanotubes (MWCNTs) increases the risk of their entry into food chains; therefore, it is necessary to assess the possibility of MWCNT removal and destruction in the gastrointestinal tract (GIT) of animals. The purpose of this study is to identify variants of destruction of industrial MWCNTs after passing through the mouse gastrointestinal tract using Raman spectroscopy and standard and analytical electron microscopy. Changes in the density of defects, wall perforations, and disintegration into small fragments have been recorded in MWCNTs isolated from feces. These changes are more clearly defined than the degradation of MWCNTs under the influence of gastric juice or hydrochloric acid alone. The nanotube biodegradation products retain their crystalline structure, which makes it possible to identify them by electron diffraction. No nanomaterial was detected in the cells or in the intercellular space of the gastric and colon mucosa. Therefore, it is shown that the gastrointestinal epithelium is an effective barrier to MWCNTs and the biodegradation of MWCNTs begins in the stomach and continues in the intestines, leading to their destruction.
Background: Pulmonary tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis). Drug-resistant TB remains a major public health challenge and calls for new approaches to drug development. Targeted delivery of antibacterial agents using nanoscale carriers represents one such approach. A decisive factor for efficient targeting is the judicious selection of the carrier platform. Methods: In the present study, diamond nanoparticles were evaluated as a prospective vehicle for conveying anti-TB drugs to lung cells. Conventional and analytical transmission electron microscopy were used to analyze the localization of the nanodiamonds (NDs) in the lungs of M. tuberculosis-infected mice 30 days after nanoparticle administration and 44 days post-infection. Results: The study shows that the NDs co-localize with M. tuberculosis in foamy macrophages of the lung, residing in the same cellular compartments—phagosomes/phagolysosomes and lipid droplets. These in vivo results demonstrate a high degree of macrophage-specific accumulation of NDs relative to M. tuberculosis. Conclusions: Consequently, NDs can be considered a promising carrier for targeted delivery of anti-TB therapeutics to the lungs during TB-induced inflammation.